MaxCyte (LON:MXCT)

MaxCyte (LON:MXCT)


Share Price
187.50 p
Change
0 (0.00 %)
Market Cap
£107.42 m
Proactive Investors - Run By Investors For Investors

MaxCyte RNS Release

Clinical and Commercial License Agreement


RNS Number : 2611H
MaxCyte, Inc.
14 November 2018
 

 

 

 

MaxCyte, Inc.

("MaxCyte")

 

Precision BioSciences and MaxCyte Enter into

Clinical and Commercial License Agreement

 

Precision BioSciences gains rights to MaxCyte's cell engineering technology to develop next-generation, oncology-focused, cell therapies with Precision's ARCUS® genome-editing technology

 

DURHAM, NC, and GAITHERSBURG, MD, 14 November 2018 - Precision BioSciences (Precision) and MaxCyte (LSE: MXCT, MXCR) today announced they have entered into a non-exclusive, clinical and commercial license agreement that will allow Precision to use MaxCyte's Flow Electroporation® technologies to robustly deliver Precision's proprietary ARCUS genome-editing technology for use in next-generation gene edited allogeneic T-cell immunotherapies designed to treat a broad range of cancers.

 

David Thomson, Chief Development Officer of Precision, expressed his support for the agreement, noting, "Precision's therapeutic grade ARCUS editing platform is sufficiently compact and specific to use with a range of delivery systems. In considering these, we have found MaxCyte's electroporation technology complements our approach to allogeneic T cell manufacturing, which is focused on preserving cell quality throughout the process while maximizing overall yield." 

 

The clinical and commercial license builds upon an existing research and clinical license agreement between Precision and MaxCyte for the delivery of Precision's ARCUS technology into T-cells. MaxCyte will supply its technology platform to Precision as part of the license agreement and will receive future payments including milestones and technology access licensing fees.

 

"The initiation of this commercial license agreement with Precision, a leader in genome editing with its own proprietary ARCUS technology, signifies a key milestone for MaxCyte and demonstrates the value and versatility of our platform, our intellectual property, and our ability to foster important collaborations with companies generating life-changing gene therapies," said Doug Doerfler, President & CEO of MaxCyte, Inc.

 

MaxCyte's Flow Electroporation Technology enables the engineering of a variety of therapeutically-relevant cell types at high efficiency while maintaining high viability and recovery. Precision's lead allogeneic CAR T programs rely on genome editing, where ARCUS tools are used to transform healthy donor cells into therapeutics using the MaxCyte technology. These cell therapies can specifically target cancer cells in patients, potentially enabling a unique and specialized approach to cancer treatment. 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

 

About Precision BioSciences

Precision BioSciences is dedicated to improving life. Our mission is to cure genetic disease, overcome cancer, and feed the planet. We are striving to achieve this goal with ARCUS, our therapeutic-grade, naturally-derived genome editing system that combines both specificity and efficacy to help overcome life's greatest genetic challenges. For additional information, please visit www.precisionbiosciences.com.

 

About MaxCyte

MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology platform to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology platform to enable its biopharmaceutical industry partners to advance the development of innovative, cutting-edge medicines, particularly in cell therapy, including the use of gene editing tools in the treatment of inherited genetic diseases and immuno-oncology approaches to treating cancer.  The Company has placed its cutting-edge flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, has more than 55 partnered programme licenses in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com

 

 For more information, visit www.maxcyte.com.

 

 

PRECISION CONTACT:

Media:

Precision BioSciences                                              +1 919 314 5512

Heather King, Director, Marketing Communications and PR

 

 

MAXCYTE CONTACTS:

 MaxCyte Inc.

 Doug Doerfler, Chief Executive Officer

 Ron Holtz, Chief Financial Officer

 

+1 301 944 1660

 

 Nominated Adviser and Broker

 Panmure Gordon

 Emma Earl

 Freddy Crossley

 Corporate Broking

 James Stearns

 

 

+44 (0)20 7886 2500

 Financial PR Adviser

 Consilium Strategic Communications

 Mary-Jane Elliott

 Chris Welsh

 Sukaina Virji

 

+44 (0)203 709 5700

[email protected]

       

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
AGRXXLLFVFFBFBZ

MaxCyte Timeline

Video
November 13 2018

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use